LB Pharmaceuticals updates S-1 with 2026 meeting results

LB Pharmaceuticals Inc filed a prospectus supplement to its Registration Statement on Form S-1 to update the Prospectus with information from a Current Report on June 9, 2026.

Rhea-AI Filing Summary

LB Pharmaceuticals Inc filed a prospectus supplement to its Registration Statement on Form S-1 to update the Prospectus with information from a Current Report on June 9, 2026.

The company held its 2026 Annual Meeting on June 3, 2026. Stockholders elected three Class I directors for three-year terms: Robert A. Lenz, M.D., Ph.D. (20,059,577 votes for), Rebecca Luse (18,530,680 votes for), and Ran Nussbaum (18,748,511 votes for). Stockholders also ratified the appointment of BDO USA, P.C. as the independent registered public accounting firm with 23,275,974 votes for.

Insights

Corporate Governance Analyst

Annual meeting confirmed board slate and auditor ratification.

The Annual Meeting on June 3, 2026 elected three Class I directors to serve three-year terms; vote totals are recorded in the filing and show clear majorities for each nominee. The meeting also ratified BDO USA, P.C. as auditor with 23,275,974 votes for.

These are routine governance outcomes. Future filings may disclose committee assignments, independence determinations, or auditor engagement terms; timing not provided in the excerpt.

Securities Compliance Advisor

Prospectus supplement links an 8-K update to the S-1 registration statement.

The supplement explicitly updates the Prospectus with information in the Current Report on June 9, 2026. The supplement is qualified by the Prospectus and should be read together with it, per the supplement language.

Disclosure items here are procedural (director elections and auditor ratification). Any offering terms remain governed by the Prospectus; no offering size, price range, or proceeds details are included in the provided excerpt.

Key Figures

Last reported sale price: $29.40 per share Votes for Robert A. Lenz: 20,059,577 votes Votes for Rebecca Luse: 18,530,680 votes +2 more

5 metrics

Last reported sale price $29.40 per share last reported sale on <date>June 8, 2026</date>

Votes for Robert A. Lenz 20,059,577 votes election as Class I director at Annual Meeting on <date>June 3, 2026</date>

Votes for Rebecca Luse 18,530,680 votes election as Class I director at Annual Meeting on <date>June 3, 2026</date>

Votes for Ran Nussbaum 18,748,511 votes election as Class I director at Annual Meeting on <date>June 3, 2026</date>

Auditor ratification votes 23,275,974 votes for ratification of BDO USA, P.C. for fiscal year ending <date>December 31, 2026</date>

Key Terms

prospectus supplement, Current Report on Form 8-K, Broker Non-Votes

3 terms

prospectus supplement regulatory

"This prospectus supplement updates, amends and supplements the prospectus dated April 14, 2026"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

Current Report on Form 8-K regulatory

"update, amend and supplement the information included in the Prospectus with the information contained in our Current Report on Form 8-K"

A current report on Form 8-K is a document that publicly traded companies file to promptly share important news or events that could affect their financial position or stock price, such as major business changes or legal issues. It helps investors stay informed about timely developments, allowing them to make better decisions about buying or selling shares.

Broker Non-Votes financial

"For | Withheld | Broker Non-Votes Robert A. Lenz, M.D., Ph.D."

Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.

Offering Details

base_shelf_indeterminate

Offering

Offering Type base_shelf_indeterminate

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did LBRX disclose in the June 9, 2026 prospectus supplement?

The supplement updates the S-1 Prospectus with the Company’s Form 8-K information. It reports the results of the 2026 Annual Meeting held on June 3, 2026, including director elections and auditor ratification.

Who was elected to LB Pharmaceuticals' board at the 2026 Annual Meeting (LBRX)?

Three Class I directors were elected for three-year terms: Robert A. Lenz, M.D., Ph.D., Rebecca Luse, and Ran Nussbaum, with vote totals of 20,059,577, 18,530,680, and 18,748,511, respectively.

Did LBRX ratify its independent auditor at the 2026 meeting?

Yes. Stockholders ratified BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 with 23,275,974 votes for.

Does the prospectus supplement disclose offering size or pricing for LBRX?

No. The supplement states it updates the Prospectus with the Form 8-K information but does not include any offering size, share count, or price-range details in the provided excerpt.

What was LBRX’s last reported sale price before the supplement date?

The supplement cites a last reported sale price of $29.40 per share on June 8, 2026 for the Company’s common stock listed on Nasdaq under the symbol LBRX.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/09/2026 - 04:09 PM Learn about SEC filing dates

Filed pursuant to Rule 424(b)(3)
Registration No. 333-294900

PROSPECTUS SUPPLEMENT

(To the Prospectus Dated April 14, 2026)

This prospectus supplement updates, amends and supplements the prospectus dated April 14, 2026 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-294900). Capitalized terms used in this prospectus supplement and not otherwise defined herein have the meanings specified in the prospectus.

This prospectus supplement is being filed to update, amend and supplement the information included in the Prospectus with the information contained in our Current Report on Form 8-K, filed with the Securities and Exchange Commission on June 9, 2026, which is set forth below.

This prospectus supplement is not complete without the Prospectus. This prospectus supplement should be read in conjunction with the Prospectus, which is to be delivered with this prospectus supplement, and is qualified by reference thereto, except to the extent that the information in this prospectus supplement updates or supersedes the information contained in the Prospectus. Please keep this prospectus supplement with your Prospectus for future reference.

Our common stock is listed on The Nasdaq Global Market under the symbol “LBRX.” On June 8, 2026, the last reported sale price of our common stock was $29.40 per share.

Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described in the section titled “Risk Factors” beginning on page 8 of the Prospectus, and under similar headings in any amendments or supplements to the Prospectus.

Neither the Securities and Exchange Commission nor any other state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of the Prospectus or this prospectus supplement. Any representation to the contrary is a criminal offense.

The date of this prospectus supplement is June 9, 2026

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 3, 2026

LB Pharmaceuticals Inc

(Exact name of registrant as specified in its charter)

Delaware		001-42831		81-1854347
(state or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

One Pennsylvania Plaza, Suite 1025 New York, NY		10119
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (212) 605-0300

Not applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		LBRX		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07. Submission of Matters to a Vote of Security Holders.

LB Pharmaceuticals Inc (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) on June 3, 2026, at which a quorum was present. The final results for each of the proposals submitted to a vote of the Company’s stockholders at the Annual Meeting are set forth below. These proposals are described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 23, 2026.

Proposal 1 – Election of Directors

The Company’s stockholders elected the three persons listed below as Class I directors, each to serve a three-year term until the Company’s 2029 Annual Meeting of Stockholders and until their successors are duly elected and qualified, or until their earlier death, resignation or removal. The final voting results were as follows:

		For		Withheld		Broker Non-Votes
Robert A. Lenz, M.D., Ph.D.		20,059,577		8,004		3,216,636
Rebecca Luse		18,530,680		1,536,901		3,216,636
Ran Nussbaum		18,748,511		1,319,070		3,216,636

Proposal 2 – Ratification of the Appointment of Independent Registered Public Accounting Firm

The Company’s stockholders ratified the appointment of BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The final voting results were as follows:

For		Against		Abstain		Broker Non-Votes
23,275,974		5,490		2,753		—

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LB PHARMACEUTICALS INC
By:		/s/ Heather Turner
		Heather Turner Chief Executive Officer

Dated: June 9, 2026